Altered Energetics of Exercise Explain Risk of Rhabdomyolysis in Very Long-Chain Acyl-CoA Dehydrogenase Deficiency

E F Diekman, G Visser, J P J Schmitz, R A J Nievelstein, M de Sain-van der Velden, M Wardrop, W L Van der Pol, S M Houten, N A W van Riel, T Takken, J A L Jeneson, E F Diekman, G Visser, J P J Schmitz, R A J Nievelstein, M de Sain-van der Velden, M Wardrop, W L Van der Pol, S M Houten, N A W van Riel, T Takken, J A L Jeneson

Abstract

Rhabdomyolysis is common in very long-chain acyl-CoA dehydrogenase deficiency (VLCADD) and other metabolic myopathies, but its pathogenic basis is poorly understood. Here, we show that prolonged bicycling exercise against a standardized moderate workload in VLCADD patients is associated with threefold bigger changes in phosphocreatine (PCr) and inorganic phosphate (Pi) concentrations in quadriceps muscle and twofold lower changes in plasma acetyl-carnitine levels than in healthy subjects. This result is consistent with the hypothesis that muscle ATP homeostasis during exercise is compromised in VLCADD. However, the measured rates of PCr and Pi recovery post-exercise showed that the mitochondrial capacity for ATP synthesis in VLCADD muscle was normal. Mathematical modeling of oxidative ATP metabolism in muscle composed of three different fiber types indicated that the observed altered energy balance during submaximal exercise in VLCADD patients may be explained by a slow-to-fast shift in quadriceps fiber-type composition corresponding to 30% of the slow-twitch fiber-type pool in healthy quadriceps muscle. This study demonstrates for the first time that quadriceps energy balance during exercise in VLCADD patients is altered but not because of failing mitochondrial function. Our findings provide new clues to understanding the risk of rhabdomyolysis following exercise in human VLCADD.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1
(A) Maximal workload of symptomatic (black squares) and asymptomatic (open squares) VLCADD patients and controls. (B) in symptomatic (black squares) and asymptomatic (open squares) VLCADD patients. (C) Fatty acid oxidation in mg/kg body mass/min in VLCADD patients and controls. Error bars indicate ± SEM. *P

Fig 2

(A) Glucose, (B) lactate and(C)…

Fig 2

(A) Glucose, (B) lactate and(C) acetylcarnitine at t = 0 (rest), t =…

Fig 2
(A) Glucose, (B) lactate and(C) acetylcarnitine at t = 0 (rest), t = 1 (directly after exercise) and t = 2 (3 hours after exercise) in symptomatic VLCADD patients and controls. Error bars indicate mean ± SEM, *P

Fig 3

(A) 31 P NMR spectra…

Fig 3

(A) 31 P NMR spectra acquired from the lateral head of the quadriceps…

Fig 3
(A) 31P NMR spectra acquired from the lateral head of the quadriceps muscle of the right leg of a VLCAD deficient patient versus a healthy control subject during 5 min of bicycling exercise at a workload equivalent to FATMAX in each subject. (B) Each spectrum represents the sum of the FIDs collected after 60 s of exercise. FIDs were apodized in the time domain using a 10-Hz low-pass filter prior to Fourier transform and phasing. Peak assignments: Pi inorganic phosphate, PCr phosphocreatine, ATP adenosine triphosphate (gamma, alpha and beta resonances, respectively). (C) Average change in PCr and Pi during exercise (in mM) in healthy control subjects versus symptomatic and asymptomatic VLCAD deficient patients. Error bars indicate mean ± SEM, *P<0.05.

Fig 4. pH dynamics during exercise and…

Fig 4. pH dynamics during exercise and first minutes of recovery.

The error bars show…

Fig 4. pH dynamics during exercise and first minutes of recovery.
The error bars show the variance in the data from AMARES fitting of the MR spectra (see Methods section). (A) Healthy controls. (B-D) VLCADD patients. Solid red lines show the fit of linear or monoexponential functions to the data; blue lines show the 95% confidence interval of the fit.

Fig 5. Pi dynamics during exercise and…

Fig 5. Pi dynamics during exercise and the first minutes of recovery rates.

The error…

Fig 5. Pi dynamics during exercise and the first minutes of recovery rates.
The error bars show the variance in the data from AMARES fitting of the MR spectra (see Methods section). (A) Healthy controls. (B-D) VLCADD patients. Solid red lines show the fit of a monoexponential function to the data; blue lines show the 95% confidence interval of the fit.
Similar articles
Cited by
References
    1. Strauss AW, Powell CK, Hale DE, Anderson MM, Ahuja A, Brackett JC, et al. Molecular basis of human mitochondrial very-long-chain acyl-CoA dehydrogenase deficiency causing cardiomyopathy and sudden death in childhood. Proc Natl Acad Sci USA. 1995;92: 10496–10500. - PMC - PubMed
    1. Houten SM, Wanders RJA. A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation. J Inherit Metab Dis. 2010;33: 469–477. 10.1007/s10545-010-9061-2 - DOI - PMC - PubMed
    1. Vianey-Saban C, Divry P, Brivet M, Nada M, Zabot MT, Mathieu M, et al. Mitochondrial very-long-chain acyl-coenzyme A dehydrogenase deficiency: clinical characteristics and diagnostic considerations in 30 patients. Clin Chim Acta. 1998;269: 43–62. - PubMed
    1. Laforêt P, Acquaviva-Bourdain C, Rigal O, Brivet M, Penisson-Besnier I, Chabrol B, et al. Diagnostic assessment and long-term follow-up of 13 patients with Very Long-Chain Acyl-Coenzyme A dehydrogenase (VLCAD) deficiency. Neuromuscul Disord. 2009;19: 324–329. 10.1016/j.nmd.2009.02.007 - DOI - PubMed
    1. Baruteau J, Sachs P, Broué P, Brivet M, Abdoul H, Vianey-Saban C, et al. Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects: a French pediatric study of 187 patients. J Inherit Metab Dis. 2012. 10.1007/s10545-012-9542-6 - DOI - PubMed
Show all 65 references
Publication types
MeSH terms
Supplementary concepts
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM
Fig 2
Fig 2
(A) Glucose, (B) lactate and(C) acetylcarnitine at t = 0 (rest), t = 1 (directly after exercise) and t = 2 (3 hours after exercise) in symptomatic VLCADD patients and controls. Error bars indicate mean ± SEM, *P

Fig 3

(A) 31 P NMR spectra…

Fig 3

(A) 31 P NMR spectra acquired from the lateral head of the quadriceps…

Fig 3
(A) 31P NMR spectra acquired from the lateral head of the quadriceps muscle of the right leg of a VLCAD deficient patient versus a healthy control subject during 5 min of bicycling exercise at a workload equivalent to FATMAX in each subject. (B) Each spectrum represents the sum of the FIDs collected after 60 s of exercise. FIDs were apodized in the time domain using a 10-Hz low-pass filter prior to Fourier transform and phasing. Peak assignments: Pi inorganic phosphate, PCr phosphocreatine, ATP adenosine triphosphate (gamma, alpha and beta resonances, respectively). (C) Average change in PCr and Pi during exercise (in mM) in healthy control subjects versus symptomatic and asymptomatic VLCAD deficient patients. Error bars indicate mean ± SEM, *P<0.05.

Fig 4. pH dynamics during exercise and…

Fig 4. pH dynamics during exercise and first minutes of recovery.

The error bars show…

Fig 4. pH dynamics during exercise and first minutes of recovery.
The error bars show the variance in the data from AMARES fitting of the MR spectra (see Methods section). (A) Healthy controls. (B-D) VLCADD patients. Solid red lines show the fit of linear or monoexponential functions to the data; blue lines show the 95% confidence interval of the fit.

Fig 5. Pi dynamics during exercise and…

Fig 5. Pi dynamics during exercise and the first minutes of recovery rates.

The error…

Fig 5. Pi dynamics during exercise and the first minutes of recovery rates.
The error bars show the variance in the data from AMARES fitting of the MR spectra (see Methods section). (A) Healthy controls. (B-D) VLCADD patients. Solid red lines show the fit of a monoexponential function to the data; blue lines show the 95% confidence interval of the fit.
Fig 3
Fig 3
(A) 31P NMR spectra acquired from the lateral head of the quadriceps muscle of the right leg of a VLCAD deficient patient versus a healthy control subject during 5 min of bicycling exercise at a workload equivalent to FATMAX in each subject. (B) Each spectrum represents the sum of the FIDs collected after 60 s of exercise. FIDs were apodized in the time domain using a 10-Hz low-pass filter prior to Fourier transform and phasing. Peak assignments: Pi inorganic phosphate, PCr phosphocreatine, ATP adenosine triphosphate (gamma, alpha and beta resonances, respectively). (C) Average change in PCr and Pi during exercise (in mM) in healthy control subjects versus symptomatic and asymptomatic VLCAD deficient patients. Error bars indicate mean ± SEM, *P<0.05.
Fig 4. pH dynamics during exercise and…
Fig 4. pH dynamics during exercise and first minutes of recovery.
The error bars show the variance in the data from AMARES fitting of the MR spectra (see Methods section). (A) Healthy controls. (B-D) VLCADD patients. Solid red lines show the fit of linear or monoexponential functions to the data; blue lines show the 95% confidence interval of the fit.
Fig 5. Pi dynamics during exercise and…
Fig 5. Pi dynamics during exercise and the first minutes of recovery rates.
The error bars show the variance in the data from AMARES fitting of the MR spectra (see Methods section). (A) Healthy controls. (B-D) VLCADD patients. Solid red lines show the fit of a monoexponential function to the data; blue lines show the 95% confidence interval of the fit.

References

    1. Strauss AW, Powell CK, Hale DE, Anderson MM, Ahuja A, Brackett JC, et al. Molecular basis of human mitochondrial very-long-chain acyl-CoA dehydrogenase deficiency causing cardiomyopathy and sudden death in childhood. Proc Natl Acad Sci USA. 1995;92: 10496–10500.
    1. Houten SM, Wanders RJA. A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation. J Inherit Metab Dis. 2010;33: 469–477. 10.1007/s10545-010-9061-2
    1. Vianey-Saban C, Divry P, Brivet M, Nada M, Zabot MT, Mathieu M, et al. Mitochondrial very-long-chain acyl-coenzyme A dehydrogenase deficiency: clinical characteristics and diagnostic considerations in 30 patients. Clin Chim Acta. 1998;269: 43–62.
    1. Laforêt P, Acquaviva-Bourdain C, Rigal O, Brivet M, Penisson-Besnier I, Chabrol B, et al. Diagnostic assessment and long-term follow-up of 13 patients with Very Long-Chain Acyl-Coenzyme A dehydrogenase (VLCAD) deficiency. Neuromuscul Disord. 2009;19: 324–329. 10.1016/j.nmd.2009.02.007
    1. Baruteau J, Sachs P, Broué P, Brivet M, Abdoul H, Vianey-Saban C, et al. Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects: a French pediatric study of 187 patients. J Inherit Metab Dis. 2012. 10.1007/s10545-012-9542-6
    1. Lindner M, Hoffmann GF, Matern D. Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting. J Inherit Metab Dis. 2010;33: 521–526. 10.1007/s10545-010-9076-8
    1. Arnold GL, VanHove J, Freedenberg D, Strauss AW, Longo N, Burton B, et al. A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. Molecular Genetics and Metabolism. Elsevier Inc; 2009;96: 85–90. 10.1016/j.ymgme.2008.09.008
    1. Orngreen MC, Madsen KL, Preisler N, Andersen G, Vissing J, Laforêt P. Bezafibrate in skeletal muscle fatty acid oxidation disorders: A randomized clinical trial. Neurology. 2014. 10.1212/WNL.0000000000000118
    1. Huerta-Alardín AL, Varon J, Marik PE. Bench-to-bedside review: Rhabdomyolysis—an overview for clinicians. Crit Care. BioMed Central Ltd; 2005;9: 158–169. 10.1186/cc2978
    1. Visweswaran P, Guntupalli J. Rhabdomyolysis. 1999;15: 415–28, ix–x.
    1. Ventura FV, Ruiter JP, Ijlst L, Almeida IT, Wanders RJ. Inhibition of oxidative phosphorylation by palmitoyl-CoA in digitonin permeabilized fibroblasts: implications for long-chain fatty acid beta-oxidation disorders. Biochim Biophys Acta. 1995;1272: 14–20.
    1. Scholte HR, Van Coster RN, de Jonge PC, Poorthuis BJ, Jeneson JA, Andresen BS, et al. Myopathy in very-long-chain acyl-CoA dehydrogenase deficiency: clinical and biochemical differences with the fatal cardiac phenotype. Neuromuscul Disord. 1999;9: 313–319.
    1. Boer den MEJ, Wanders RJA, Morris AAM, IJLst L, Heymans HSA, Wijburg FA. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: clinical presentation and follow-up of 50 patients. Pediatrics. 2002;109: 99–104.
    1. Boer den MEJ, Dionisi-Vici C, Chakrapani A, van Thuijl AOJ, Wanders RJA, Wijburg FA. Mitochondrial trifunctional protein deficiency: a severe fatty acid oxidation disorder with cardiac and neurologic involvement. J Pediatr. 2003;142: 684–689. 10.1067/mpd.2003.231
    1. Bonnefont JP, Demaugre F, Prip-Buus C, Saudubray JM, Brivet M, Abadi N, et al. Carnitine palmitoyltransferase deficiencies. Molecular Genetics and Metabolism. 1999;68: 424–440. 10.1006/mgme.1999.2938
    1. Rubio-Gozalbo ME, Bakker JA, Waterham HR, Wanders RJA. Carnitine-acylcarnitine translocase deficiency, clinical, biochemical and genetic aspects. Mol Aspects Med. 2004;25: 521–532. 10.1016/j.mam.2004.06.007
    1. Morris AA, Turnbull DM. Fatty acid oxidation defects in muscle. Curr Opin Neurol. 1998;11: 485–490.
    1. Vissing CR, Dunø M, Olesen JH, Rafiq J, Risom L, Christensen E, et al. Recurrent myoglobinuria and deranged acylcarnitines due to a mutation in the mtDNA MT-CO2 gene. Neurology. 2013;80: 1908–1910. 10.1212/WNL.0b013e3182929fb2
    1. Piper MH, Sezer O, Schwartz P, Hütter JF, Schweickhardt C, Spieckermann PG. Acyl-carnitine effects on isolated cardiac mitochondria and erythrocytes. Basic Res Cardiol. 1984;79: 186–198.
    1. Watanabe H, Kobayashi A, Hayashi H. Effects of long-chain acyl carnitine on membrane fluidity of human erythrocytes. Biochimica et Biophysica …. 1989. 10.1016/0005-2736(89)90318-0
    1. Kahle M, Schäfer A, Seelig A, Schultheiß J, Wu M, Aichler M, et al. High fat diet-induced modifications in membrane lipid and mitochondrial-membrane protein signatures precede the development of hepatic insulin resistance in mice. Molecular Metabolism. 2015;4: 39–50. 10.1016/j.molmet.2014.11.004
    1. Meyer RA. A linear model of muscle respiration explains monoexponential phosphocreatine changes. Am J Physiol. 1988;254: C548–53.
    1. Jeneson JAL, Schmitz JPJ, Hilbers PAJ, Nicolay K. An MR-compatible bicycle ergometer for in-magnet whole-body human exercise testing. Magn Reson Med. 2010;63: 257–261. 10.1002/mrm.22179
    1. van Brussel M, van Oorschot JWM, Schmitz JPJ, Nicolay K, van Royen-Kerkhof A, Takken T, et al. Muscle Metabolic Responses During Dynamic In-Magnet Exercise Testing: A Pilot Study in Children with an Idiopathic Inflammatory Myopathy. Acad Radiol. Elsevier; 2015;0: 1443–1448. 10.1016/j.acra.2015.06.013
    1. Zakrzewski J, Tolfrey K. Exercise protocols to estimate Fatmax and maximal fat oxidation in children. Pediatr Exerc Sci. 2011;23: 122–135.
    1. Achten J, Gleeson M, Jeukendrup AE. Determination of the exercise intensity that elicits maximal fat oxidation. Med Sci Sports Exerc. 2002;34: 92–97.
    1. Péronnet F, Massicotte D. Table of nonprotein respiratory quotient: an update. Can J Sport Science. 1991;16: 23–29.
    1. Jeneson JA, Wiseman RW, Kushmerick MJ. Non-invasive quantitative 31P MRS assay of mitochondrial function in skeletal muscle in situ. Mol Cell Biochem. 1997;174: 17–22.
    1. Bottinelli R, Reggiani C. Human skeletal muscle fibres: molecular and functional diversity. Prog Biophys Mol Biol. 2000;73: 195–262.
    1. Rowell LB, Shepherd JT. Handbook of Physiology: Exercise: regulation and integration of multiple systems.
    1. Hultman E. Fuel selection, muscle fibre. Proc Nutr Soc. 1995;54: 107–121.
    1. van Oorschot JWM, Schmitz JPJ, Webb A, Nicolay K, Jeneson JAL, Kan HE. 31P MR spectroscopy and computational modeling identify a direct relation between Pi content of an alkaline compartment in resting muscle and phosphocreatine resynthesis kinetics in active muscle in humans. PLoS ONE. 2013;8: e76628 10.1371/journal.pone.0076628
    1. Staron RS, Hagerman FC, Hikida RS, Murray TF, Hostler DP, Crill MT, et al. Fiber type composition of the vastus lateralis muscle of young men and women. J Histochem Cytochem. 2000;48: 623–629. 10.1177/002215540004800506
    1. Veld ter F, Nicolay K, Jeneson JAL. Increased resistance to fatigue in creatine kinase deficient muscle is not due to improved contractile economy. Pflugers Arch. 2006;452: 342–348. 10.1007/s00424-005-0041-6
    1. Jeneson JAL, Veld ter F, Schmitz JPJ, Meyer RA, Hilbers PAJ, Nicolay K. Similar mitochondrial activation kinetics in wild-type and creatine kinase-deficient fast-twitch muscle indicate significant Pi control of respiration. Am J Physiol Regul Integr Comp Physiol. 2011;300: R1316–25. 10.1152/ajpregu.00204.2010
    1. de Sain-van der Velden MGM, Diekman EF, Jans JJ, van der Ham M, Prinsen BHCMT, Visser G, et al. Differences between acylcarnitine profiles in plasma and bloodspots. Molecular Genetics and Metabolism. 2013. 10.1016/j.ymgme.2013.04.008
    1. Bergmeyer HU. Methods of Enzymatic Analysis. Wiley-VCH; 1986.
    1. Chuang C-K, Wang T-J, Yeung C-Y, Lin D-S, Lin H-Y, Liu H-L, et al. A method for lactate and pyruvate determination in filter-paper dried blood spots. J Chromatogr A. 2009;1216: 8947–8952. 10.1016/j.chroma.2009.10.074
    1. Violante S, IJLst L, van Lenthe H, de Almeida IT, WANDERS RJ, Ventura FV. Carnitine palmitoyltransferase 2: New insights on the substrate specificity and implications for acylcarnitine profiling. Biochim Biophys Acta. 2010;1802: 728–732. 10.1016/j.bbadis.2010.06.002
    1. Dawson MJ, Gadian DG, Wilkie DR. Muscular fatigue investigated by phosphorus nuclear magnetic resonance. Nature. 1978. 10.1038/274861a0
    1. Allen DG, Lamb GD, Westerblad H. Skeletal muscle fatigue: cellular mechanisms. Physiological Reviews. 2008;88: 287–332. 10.1152/physrev.00015.2007
    1. Jeneson JA, Westerhoff HV, Kushmerick MJ. A metabolic control analysis of kinetic controls in ATP free energy metabolism in contracting skeletal muscle. Am J Physiol, Cell Physiol. 2000;279: C813–32.
    1. Atkinson DF. Journal of Food Biochemistry. J Food Biochemistry. 1978;2: 209–217. 10.1111/j.1745-4514.1978.tb00613.x
    1. Arnold DL, Taylor DJ, Radda GK. Investigation of human mitochondrial myopathies by phosphorus magnetic resonance spectroscopy. Ann Neurol. 1985;18: 189–196. 10.1002/ana.410180205
    1. Wu F, Jeneson JAL, Beard DA. Oxidative ATP synthesis in skeletal muscle is controlled by substrate feedback. Am J Physiol, Cell Physiol. 2007;292: C115–24. 10.1152/ajpcell.00237.2006
    1. From AH, Petein MA, Michurski SP, Zimmer SD, Uğurbil K. 31P-NMR studies of respiratory regulation in the intact myocardium. FEBS Lett. 1986;206: 257–261.
    1. Kim DK, Heineman FW, Balaban RS. Effects of beta-hydroxybutyrate on oxidative metabolism and phosphorylation potential in canine heart in vivo. Am J Physiol. 1991;260: H1767–73.
    1. Jeneson JAL, de Snoo MW, Verlinden NAT, Joosten BJLJ, Doornenbal A, Schot A, et al. Treadmill but not wheel running improves fatigue resistance of isolated extensor digitorum longus muscle in mice. Acta Physiol (Oxf). 2007;190: 151–161. 10.1111/j.1748-1716.2007.01680.x
    1. Diekman EF, Pol WL, Nievelstein RAJ, Houten SM, Wijburg FA, Visser G. Muscle MRI in patients with long-chain fatty acid oxidation disorders. J Inherit Metab Dis. 2013. 10.1007/s10545-013-9666-3
    1. Tucci S, Herebian D, Sturm M, Seibt A, Spiekerkoetter U. Tissue-Specific Strategies of the Very-Long Chain Acyl-CoA Dehydrogenase-Deficient (VLCAD−/−) Mouse to Compensate a Defective Fatty Acid β-Oxidation. Guerrero-Hernandez A, editor. PLoS ONE. 2012;7: e45429 10.1371/journal.pone.0045429.t002
    1. York B, Reineke EL, Sagen JV, Nikolai BC, Zhou S, Louet J-F, et al. Ablation of steroid receptor coactivator-3 resembles the human CACT metabolic myopathy. Cell Metabolism. 2012;15: 752–763. 10.1016/j.cmet.2012.03.020
    1. Dunn JF, Frostick S, Brown G, Radda GK. Energy status of cells lacking dystrophin: an in vivo/in vitro study of mdx mouse skeletal muscle. Biochim Biophys Acta. 1991;1096: 115–120. 10.1016/0925-4439(91)90048-E
    1. Barbiroli B, McCully KK, Iotti S, Lodi R, Zaniol P, Chance B. Further impairment of muscle phosphate kinetics by lengthening exercise in DMD/BMD carriers. J Neurol Sci. 1993;119: 65–73. 10.1016/0022-510X(93)90192-2
    1. Tosetti M, Linsalata S, Battini R, Volpi L, Cini C, Presciutti O, et al. Muscle metabolic alterations assessed by 31-phosphorus magnetic resonance spectroscopy in mild Becker muscular dystrophy. Muscle Nerve. 2011;44: 816–819. 10.1002/mus.22181
    1. Dennett X, Shield LK, Clingan LJ, Woolley DA. Becker and Duchenne muscular dystrophy: a comparative morphological study. Aust Paediatr J. 1988;24 Suppl 1: 15–20.
    1. Kihira S, Nonaka I. Congenital muscular dystrophy. A histochemical study with morphometric analysis on biopsied muscles. J Neurol Sci. 1985;70: 139–149.
    1. Webster C, Silberstein L, Hays AP, Blau HM. Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell. 1988;52: 503–513. 10.1016/0092-8674(88)90463-1
    1. Weibel ER, Taylor CR, Weber JM, Vock R, Roberts TJ, Hoppeler H. Design of the oxygen and substrate pathways. VII. Different structural limits for oxygen and substrate supply to muscle mitochondria. J Exp Biol. 1996;199: 1699–1709.
    1. McBride A, Ghilagaber S, Nikolaev A, Hardie DG. The glycogen-binding domain on the AMPK beta subunit allows the kinase to act as a glycogen sensor. Cell Metabolism. 2009;9: 23–34. 10.1016/j.cmet.2008.11.008
    1. Kushmerick MJ, Meyer RA. Chemical changes in rat leg muscle by phosphorus nuclear magnetic resonance. American Journal of Physiology- …. 1985.
    1. Brumback RA. Iodoacetate inhibition of glyceraldehyde-3-phosphate dehydrogenase as a model of human myophosphorylase deficiency (McArdle's disease) and …. J Neurol Sci. 1980;48: 383–398. 10.1016/0022-510X(80)90110-0
    1. Milone M, Wong L-J. Diagnosis of mitochondrial myopathies. Molecular Genetics and Metabolism. 2013;110: 35–41. 10.1016/j.ymgme.2013.07.007
    1. Roberts LD, Boström P, O’Sullivan JF, Schinzel RT, Lewis GD, Dejam A, et al. β-Aminoisobutyric Acid Induces Browning of White Fat and Hepatic β-Oxidation and Is Inversely Correlated with Cardiometabolic Risk Factors. Cell Metabolism. 2014;19: 96–108. 10.1016/j.cmet.2013.12.003
    1. Veech RL, Chance B, Kashiwaya Y, Lardy HA, Cahill GF. Ketone Bodies, Potential Therapeutic Uses. IUBMB Life. Informa Healthcare; 2001;51: 241–247. 10.1080/152165401753311780
    1. Westerhoff HV, van Echteld CJ, Jeneson JA. On the expected relationship between Gibbs energy of ATP hydrolysis and muscle performance. Biophys Chem. 1995;54: 137–142.

Source: PubMed

3
Abonner